Recce Pharmaceuticals Furthers Ongoing Phase I/II Clinical Trial of RECCE® 327 Targeting Diabetic Foot Ulcer Infections with Expanded Patient Recruitment

Overview Company: Recce Pharmaceuticals Ltd Indication: Diabetic Foot Infections Drug: RECCE® 327 Trial Phase: Phase 1/2 NCT ID: N/A Trial Expansion Announcement Recce Pharmaceuticals Ltd has expanded the patient recruitment for their ongoing Phase I/II clinical trial evaluating the synthetic anti-infective agent, RECCE® 327, for the treatment of Diabetic Foot Ulcer Infections. Background Diabet..